- In a note, Canaccord's Mark Massaro says diagnostic companies are outperforming this year, with CareDx (NASDAQ:CDNA) and Foundation Medicine (NASDAQ:FMI)(acquired by Roche) leading the way.
- Top gainers are: HTG Molecular Diagnostics (NASDAQ:HTGM), Genomic Health (NASDAQ:GHDX), GenMark Diagnostics (NASDAQ:GNMK), Quidel (NASDAQ:QDEL), Illumina (NASDAQ:ILMN), IDEXX Laboratories (NASDAQ:IDXX), T2 Biosystems (NASDAQ:TTOO), Exact Sciences (NASDAQ:EXAS) and Heska (NASDAQ:HSKA).
- Pure-plays with M&A potential: ILMN, HSKA, GNMK, QDEL, EXAS, TTOO, HTGM, OraSure Technologies (NASDAQ:OSUR) and Natera (NASDAQ:NTRA).
- Top picks: IDXX, EXAS, LabCorp (NYSE:LH), NTRA, OSUR.